CONNEQT Health Reports Record $1.3M Consumer Revenue and Advances FDA Review for SphygmoCloud Platform

Record Consumer Revenue and Accelerated Digital Monetisation in June Quarter

CONNEQT Health’s consumer segment delivered its strongest quarterly revenue performance in June 2026, achieving $1.3 million, a 21% increase from the March quarter and 34% on a constant currency basis. This reflects strong commercial traction across multiple sales channels for the CONNEQT Pulse connected blood pressure monitor, the core of the company’s consumer strategy. Notably, this quarter marked the first time CONNEQT generated over US$1 million in cash receipts from consumer operations, underscoring sustainable revenue growth at scale.

Unit sales of the CONNEQT Pulse device increased 33% quarter-on-quarter to 3,574 units, expanding the consumer installed base and strengthening the connected user ecosystem. This growth is strategically vital as it enables multiple recurring revenue opportunities beyond initial hardware sales. Digital subscriptions and in-app purchases grew 71% quarter-on-quarter to $68,000, outpacing hardware sales and validating the company’s software monetisation approach. Digital subscriptions now account for 5% of consumer revenue, up from 4% last quarter, indicating progress toward higher-margin recurring revenue streams.

Enhancing Customer Lifetime Value and Premium Service Adoption

Data indicates customers purchasing premium digital services deliver an estimated lifetime value of approximately $168 (US$114) per purchaser, supporting CONNEQT’s strategy to extend value beyond initial hardware sales. This metric highlights the potential for multiple revenue events per device through software, subscriptions, and digital health services. The company continues investing in bundled subscription packages, onboarding processes, and premium software features to boost customer engagement and lifetime value.

CONNEQT Pulse was named Best Advanced Blood Pressure Monitor of 2026 by the National Council on Aging (NCOA), providing third-party validation of its clinical quality and market position. This endorsement enhances brand recognition and scientific credibility, supporting clinical validation and regulatory efforts while strengthening commercial positioning in the competitive digital health monitoring market.

FDA Pre-Submission for SphygmoCloud Advances SaMD Strategy

In the June quarter, CONNEQT Health submitted an FDA Pre-Submission package for SphygmoCloud, its cloud-based cardiovascular analytics Software as a Medical Device (SaMD) platform. This milestone advances the company’s strategy to develop regulated cloud analytics complementing its consumer and research businesses. The FDA Pre-Submission process provides regulatory guidance prior to formal application, aligning product development and clinical validation with regulatory expectations.

SphygmoCloud expands CONNEQT’s addressable market beyond consumer and enterprise segments into regulated software, where recurring subscriptions and higher margins are common. Its cloud architecture offers advanced cardiovascular analytics to healthcare providers, supporting clinical decision-making and patient monitoring. Successful FDA review would validate the product strategy and unlock significant enterprise and clinical adoption opportunities in hospitals, healthcare systems, and cardiology practices.

Enterprise Subscriptions Build Recurring Revenue Base

CONNEQT’s enterprise segment scaled further in the June quarter by onboarding additional clinical subscription sites, validating its recurring, usage-based business model. This transition from traditional capital equipment sales to long-term customer relationships enhances predictable recurring revenue. The enterprise subscriptions segment began generating material recurring revenue during FY26, diversifying away from one-time hardware and research service sales.

Growing the enterprise installed base lays the foundation for increased utilisation and recurring revenue. As clinical sites integrate CONNEQT solutions into workflows, opportunities arise to expand usage, add services, or raise subscription fees, improving revenue visibility and customer retention compared to transactional sales.

Diversified FY26 Revenue and Three-Segment Business Model

FY26 marked a commercial inflection for CONNEQT Health, with total revenue rising 73% to $6.3 million. Revenue is now balanced across three segments: consumer revenue reached $4.0 million, driven by CONNEQT Pulse sales; research operations contributed $2.3 million from pharmaceutical, academic, clinical, and international sales, strengthening scientific credibility; and enterprise subscriptions established a recurring revenue stream, shifting away from traditional capital sales.

Including other income of approximately $1.6 million, total Group revenue and other income reached around $8 million in FY26. The June quarter results imply an annualised run-rate near $10 million. This three-pillar revenue model reduces dependence on any single segment, providing multiple growth avenues: consumer expands reach and installed base, research supports scientific leadership, and enterprise subscriptions offer predictable recurring revenue.

Capital Raise Fuels Growth and Enhances Balance Sheet

During the June quarter, CONNEQT Health completed a $5.5 million institutional placement to fund commercial expansion and strengthen its balance sheet. The placement was well received by institutional investors, reflecting confidence in the company’s strategy and execution. Closing cash was $2.6 million at quarter-end, with an additional $0.8 million expected from Tranche 2 and proceeds from an ongoing Share Purchase Plan (SPP).

The capital raised supports investments in commercial growth, product development, and enterprise expansion while maintaining a lean operating model. Management emphasizes disciplined capital allocation focused on high-return opportunities in consumer acquisition, enterprise sales, and software platform development. The funding provides flexibility to accelerate growth initiatives, pursue strategic partnerships, and manage market uncertainties.

Disciplined Operating Model Balances Growth and Financial Control

Throughout FY26 and the June quarter, CONNEQT Health maintained a lean operating structure while investing in growth areas such as commercial expansion, product innovation, and enterprise scaling. This disciplined approach prioritizes profitable growth and sustainable business economics over unchecked expansion. The company’s record consumer revenue and multi-segment growth alongside financial discipline indicate effective operational management and strategic investment prioritization.

The balance between efficiency and strategic spending is evident as total revenue grew 73% in FY26 with an annualised run-rate near $10 million by June quarter-end. This suggests CONNEQT is scaling without proportional cost increases, signaling operational leverage and margin expansion potential. Management plans to continue executing its commercial strategy across consumer, enterprise, and software platforms while maintaining capital discipline into FY27.

Multiple Growth Drivers Set Stage for FY27 Expansion

Entering FY27, CONNEQT Health is positioned with several growth drivers across its segments. The consumer business benefits from rising brand awareness, optimized customer acquisition, and normalized product availability post supply chain improvements. Pulse device sales remain the primary growth engine, with strong unit growth and accelerating digital subscriptions.

The research segment continues to deliver diversified revenue and scientific validation, underpinning credibility in cardiovascular monitoring and digital health. The enterprise subscriptions business is expanding with new clinical sites, building a growing installed base for increased utilisation and recurring revenue. The FDA Pre-Submission for SphygmoCloud initiates a regulatory pathway that could unlock substantial opportunities in regulated software markets. Combined with an improved capital position from the placement and SPP, CONNEQT is well positioned for accelerated growth across all three business segments.

SaMD Strategy and Regulatory Progress Offer Long-Term Value Potential

CONNEQT Health’s advancement of its Software as a Medical Device (SaMD) strategy via the FDA Pre-Submission for SphygmoCloud represents a significant long-term value creation opportunity. The SaMD sector attracts strong investment and acquisition interest from major healthcare technology and pharmaceutical companies, with cloud-based analytics platforms commanding premium valuations and recurring revenue streams. FDA clearance or approval of SphygmoCloud would enable CONNEQT to scale enterprise and clinical customer engagement substantially.

The regulatory pathway for cloud cardiovascular analytics is increasingly established, with several companies having achieved FDA approvals. CONNEQT’s Pre-Submission filing reflects a methodical approach to understanding FDA requirements before full submission. A successful FDA outcome could facilitate partnerships with leading healthcare technology vendors, clinical trial organisations, healthcare systems, and pharmaceutical firms seeking advanced cardiovascular analytics. This regulatory progress, combined with strong consumer and enterprise momentum, positions CONNEQT to capitalize on multiple market opportunities as digital health continues to evolve.